SK Bio-Pharmaceuticals

> International bio-pharmaceutical company headquartered in Fair Lawn, NJ, accessing 60 research scientists in the United States, Korea, and China.

> Specializes in the discovery and development of small molecule drug candidates from drug target through commercialization.

> Expertise in combinatorial chemistry and functional genomics drive and accelerated discovery process that optimizes the design of new chemical entities.

> Two CNS compounds in Phase II clinical development.

> Strategic collaboration with Johnson & Johnson for the global development and marketing of an antidepressant compound (YKP10A) and an antiepileptic (YKP509).

> Deep pipeline, with products targeted at epilepsy, depression, schizophrenia, anxiety, diabetes, and asthma.

> Founded in 1993 as a wholly-owned subsidiary of SK Corporation, one of 40 companies on six continents that comprise the SK Group, the third largest conglomerate in Korea.

For more information, please send an e-mail to info@skbp.com.